Amicus Therapeutics, INC Form 4 insider transactions

Amicus Therapeutics' Chief Legal Officer, Ellen Rosenberg, executed pre-planned stock option exercises and subsequent sales of common stock.

Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,643 shares of common stock for approximately $9.51 per share under a pre-arranged 10b5-1 trading plan.

Amicus Therapeutics' Chief Financial Officer, Simon N.R. Harford, reported the disposition of 12,529 common shares at $7.60 each, primarily for tax withholding purposes.

Amicus Therapeutics Director Margaret G. McGlynn received grants of 20,414 Restricted Stock Units and 74,872 stock options on June 5, 2025, increasing her beneficial ownership in the company.

Amicus Therapeutics, Inc. Director Michael Raab was granted 20,414 Restricted Stock Units and options to purchase 74,872 shares of common stock, effective June 5, 2025.

Amicus Therapeutics, Inc. Director Glenn Sblendorio was granted 20,414 Restricted Stock Units and options to purchase 74,872 shares of common stock, aligning his interests with long-term shareholder value.

Amicus Therapeutics, Inc. Director Michael Aaron Kelly was granted 20,414 Restricted Stock Units and 74,872 stock options on June 5, 2025, as part of his compensation.

Amicus Therapeutics, Inc. Director Eiry Roberts acquired 20,414 shares of common stock through Restricted Stock Units and 74,872 stock options on June 5, 2025, increasing her beneficial ownership.

Amicus Therapeutics, Inc. Director Lynn Dorsey Bleil was granted 20,414 Restricted Stock Units and 74,872 stock options, vesting one year from the grant date of June 5, 2025.

Amicus Therapeutics, Inc. Director Craig A. Wheeler has increased his beneficial ownership through the grant of 20,414 Restricted Stock Units and 74,872 stock options, signaling continued alignment with shareholder interests.

Amicus Therapeutics, Inc. Director Burke W. Whitman was granted 20,414 Restricted Stock Units and 74,872 stock options as part of his compensation.

Bradley L. Campbell, President and CEO of Amicus Therapeutics, reports the disposition of 13,375 shares of common stock on March 15, 2025.

Amicus Therapeutics' CEO, Bradley L. Campbell, exercised stock options and sold a small portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Samantha Prout, Chief Accounting Officer of Amicus Therapeutics, reports acquisition and disposal of company stock on February 11, 2025.

Chief Development Officer Jeff Castelli reports acquisition of shares through Performance Restricted Stock Units (PRSUs) and disposal of shares to cover tax obligations.

David Michael Clark, Chief People Officer of Amicus Therapeutics, reports acquisition of shares related to performance stock units and disposition of shares to cover tax obligations.

Amicus Therapeutics' CEO, Bradley Campbell, reports acquisition of shares through performance-based restricted stock units (PRSUs) and disposition of shares to cover tax obligations.

Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, reports acquisition and disposal of common stock.

Amicus Therapeutics' Chief Legal Officer, Ellen Rosenberg, reported multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Chief Accounting Officer of Amicus Therapeutics, Samantha Prout, reports multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Amicus Therapeutics' Chief People Officer, David Michael Clark, reported multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Amicus Therapeutics CEO Bradley Campbell reported multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Chief Development Officer of Amicus Therapeutics, Jeff Castelli, reports multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Amicus Therapeutics' Chief Financial Officer, Simon N.R. Harford, reported the acquisition of restricted stock units and stock options, along with the disposal of shares to cover tax obligations.

Amicus Therapeutics' CEO, Bradley L. Campbell, executed a pre-planned transaction involving the exercise of stock options and the sale of common stock.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Amicus Therapeutics' CEO, Bradley L. Campbell, exercised stock options and sold shares on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Amicus Therapeutics CEO Bradley L. Campbell executed stock options and sold shares on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Simon N.R. Harford, CFO of Amicus Therapeutics, disposed of 12,529 shares of common stock on August 21, 2024, to cover tax obligations.